Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes.
Adema V, Ganan-Gomez I, Ma F, Rodriguez-Sevilla JJ, Chien K, Yang H, Thongon N, Kanagal-Shamanna R, Loghavi S, Montalban-Bravo G, Hammond D, Gu Y, Tan R, Tan L, Lorenzi P, Al-Atrash G, Clise-Dwyer K, Bejar R, Pellegrini M, Garcia-Manero G, Colla S. Adema V, et al. Among authors: hammond d. bioRxiv [Preprint]. 2023 Sep 30:2023.09.28.560018. doi: 10.1101/2023.09.28.560018. bioRxiv. 2023. PMID: 37808770 Free PMC article. Preprint.
Clonal haematopoiesis of emerging significance.
Hammond D, Loghavi S. Hammond D, et al. Pathology. 2021 Apr;53(3):300-311. doi: 10.1016/j.pathol.2021.02.005. Epub 2021 Mar 6. Pathology. 2021. PMID: 33685721 Review.
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. DiNardo CD, et al. Among authors: hammond d. Blood Adv. 2023 Jun 13;7(11):2378-2387. doi: 10.1182/bloodadvances.2022008378. Blood Adv. 2023. PMID: 35973199 Free PMC article.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bazinet A, et al. Among authors: hammond d. Cancer. 2023 Feb 15;129(4):560-568. doi: 10.1002/cncr.34564. Epub 2022 Dec 2. Cancer. 2023. PMID: 36458426 Free article.
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Siddiqui M, et al. Among authors: hammond d. Am J Hematol. 2023 Apr;98(4):E91-E94. doi: 10.1002/ajh.26858. Epub 2023 Feb 1. Am J Hematol. 2023. PMID: 36661399 Free article. No abstract available.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: hammond d. Br J Haematol. 2023 Nov;203(4):581-592. doi: 10.1111/bjh.19060. Epub 2023 Aug 22. Br J Haematol. 2023. PMID: 37608562
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Bataller A, et al. Among authors: hammond d. Am J Hematol. 2023 Nov;98(11):1780-1790. doi: 10.1002/ajh.27070. Epub 2023 Sep 4. Am J Hematol. 2023. PMID: 37665752
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: hammond d. Br J Haematol. 2024 Mar;204(3):898-909. doi: 10.1111/bjh.19193. Epub 2023 Nov 10. Br J Haematol. 2024. PMID: 37946611 Clinical Trial.
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Among authors: hammond d. Clin Cancer Res. 2024 Apr 1;30(7):1319-1326. doi: 10.1158/1078-0432.CCR-23-2860. Clin Cancer Res. 2024. PMID: 38300723
1,549 results